Trial Profile
Phase I/II Study Investigating the Safety of ADV Specific T Cells in High-risk Paediatric Patients Post Allo-HSCT to Treat ADV Reactivation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Apr 2020
Price :
$35
*
At a glance
- Drugs Adenovirus specific T cells Cell Medica (Primary)
- Indications Adenovirus infections
- Focus Adverse reactions; First in man
- Acronyms ASPIRE
- Sponsors Cell Medica; Kuur Therapeutics
- 10 Mar 2020 According to an Kuur Therapeutics media release, Cell Medica has changed its name to Kuur Therapeutics.
- 01 Aug 2018 According to a Cell Medica media release, results of this study have been published in Cytotherapy Journal (2018).
- 01 Aug 2018 Results presented in a Cell Medica media release.